Moore Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Moore Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-90,000	Closed	-$7.86M	–	458
2024 Q1	$7.86M	Buy	90,000 +15,000	+20%	+$1.34M	0.13%	145
2023 Q4	$7.23M	Buy	+75,000	New	+$6.64M	0.12%	120
2023 Q3	–	Sell	-30,000	Closed	-$2.6M	–	509
2023 Q2	$2.6M	Buy	+30,000	New	+$2.82M	0.04%	229

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Moore Capital Management's BMRN Position: Q1 2026 in Review

Moore Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 325,000 shares — an estimated $19.3M sold.

Moore Capital Management first reported a position in BMRN in Q3 2013 and held it in 16 quarters. The position peaked at $22.7M in Q1 2024. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Moore Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Moore Capital Management sold 325,000 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $19.3M.
Moore Capital Management first reported a position in BioMarin Pharmaceuticals in Q3 2013 and held it in 16 quarters.
Moore Capital Management's BioMarin Pharmaceuticals position peaked at $22.7M in Q1 2024.
555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Moore Capital Management's 13F filing for Q1 2026, filed 15 May 2026.